# Resveratrol in Type2 Diabetes and Obesity

> **NCT01158417** · NA · TERMINATED · sponsor: **University at Buffalo** · enrollment: 15 (actual)

## Conditions studied

- Type 2 Diabetes
- Obesity
- Insulin Resistance

## Interventions

- **DRUG:** Placebo
- **DRUG:** Resveratrol 40 mg oral three times a day
- **DRUG:** Resveratrol 500 mg oral once daily.

## Key facts

- **NCT ID:** NCT01158417
- **Lead sponsor:** University at Buffalo
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2012-07-08
- **Final completion:** 2012-07-08
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** FDA clinical hold requiring IND submission, product not available in the market anymore
- **Last updated:** 2022-11-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158417, "Resveratrol in Type2 Diabetes and Obesity". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01158417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*